1. Levinthal GN, Tavill AS. Liver disease and diabetes mellitus. Clin Diabetes 1999;17:1-20.
2. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Haring HU, Nawratil P, Haasemann M, Jahnen-Dechent W, Muller-Esterl W. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 1992;204:523-529.
Article PubMed
3. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58:631-640.
Article PubMed
4. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450-2458.
Article PubMed
5. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;3:e1765.
Article PubMed PMC
6. Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY. Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 2018;55:87-98.
Article PubMed
7. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG;. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008;300:182-188.
Article PubMed PMC
8. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Schulze MB. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767.
Article PubMed PMC
9. Ix JH, Biggs ML, Mukamal KJ, Kizer JR, Zieman SJ, Siscovick DS, Mozzaffarian D, Jensen MK, Nelson L, Ruderman N, Djousse L. Association of fetuin-A with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation 2012;125:2316-2322.
PubMed PMC
10. Laughlin GA, Barrett-Connor E, Cummins KM, Daniels LB, Wassel CL, Ix JH. Sex-specific association of fetuin-A with type 2 diabetes in older community-dwelling adults: the Rancho Bernardo study. Diabetes Care 2013;36:1994-2000.
Article PubMed PMC
11. Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 2013;62:49-55.
Article PubMed
12. Aroner SA, Mukamal KJ, St-Jules DE, Budoff MJ, Katz R, Criqui MH, Allison MA, de Boer IH, Siscovick DS, Ix JH, Jensen MK. Fetuin-a and risk of diabetes independent of liver fat content: the multi-ethnic study of atherosclerosis. Am J Epidemiol 2017;185:54-64.
Article PubMed
13. Dutta D, Mondal SA, Kumar M, Hasanoor Reza AH, Biswas D, Singh P, Chakrabarti S, Mukhopadhyay S. Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India. Diabet Med 2014;31:1594-1599.
Article PubMed
14. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013;1281:64-91.
Article PubMed PMC
15. Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, Shikata K, Iida M, Kiyohara Y. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 2007;15:1841-1850.
Article PubMed
16. Wang YL, Koh WP, Yuan JM, Pan A. Association between liver enzymes and incident type 2 diabetes in Singapore Chinese men and women. BMJ Open Diabetes Res Care 2016;4:e000296.
PubMed PMC
17. Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study. Diabet Med 2016;33:348-355.
Article
18. Kunutsor SK, Apekey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. Am J Epidemiol 2013;178:159-171.
PubMed
19. Chan JC, Yeung R, Luk A. The Asian diabetes phenotypes: challenges and opportunities. Diabetes Res Clin Pract 2014;105:135-139.
Article
20. Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, Yu MC. Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer 2001;39:187-195.
PubMed
21. Odegaard AO, Pereira MA, Koh WP, Arakawa K, Lee HP, Yu MC. Coffee, tea, and incident type 2 diabetes: the Singapore Chinese Health Study. Am J Clin Nutr 2008;88:979-985.
Article PubMed PMC
22. Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest 2018;41:33-47.
Article
23. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:4479-4485.
PubMed
24. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 2005;54:2477-2481.
PubMed
25. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010;21:406-412.
PubMed PMC
26. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-188.
PubMed
27. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760-1767.
Article PubMed PMC
28. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, Bhattacharya S. NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J 2010;429:451-462.
Article PubMed
29. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-857.
Article PubMed
30. Stefan N, Schick F, Haring HU. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:2236-2237.
Article
31. Stefan N, Sun Q, Fritsche A, Machann J, Schick F, Gerst F, Jeppesen C, Joost HG, Hu FB, Boeing H, Ullrich S, Haring HU, Schulze MB. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One 2014;9:e92238.
Article PubMed PMC
32. Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, Mantzoros CS, Ricchiuti V, Willett WC, Hankinson SE, Eliassen AH. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010;19:938-946.
Article PubMed PMC
33. Stefan N, Haring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 2013;19:394-395.
Article PubMed
34. Mori K, Emoto M, Araki T, Yokoyama H, Lee E, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 2008;57:1248-1252.
Article PubMed
35. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 2010;95:4877-4881.
Article PubMed